Isarna presents positive preclinical results supporting development of ISTH0036 for the treatment of glaucoma

Isarna Therapeutics, the leader in transforming growth factor beta (TGF-ß) isoform targeted antisense therapeutics, today announced the presentation of preclinical data for its lead candidate...